MEDIA ADVISORY – Oncolytics Biotech® Inc. to Present at 13th Annual BIO CEO & Investor Conference

CALGARY, Feb. 10 /PRNewswire-FirstCall/ – Dr. Brad Thompson, President and CEO of
Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a
corporate overview of the Company at the 13th Annual BIO CEO & Investor Conference on Monday, February 14th, 2011 at 4:00 p.m. ET. Hosted by the Biotechnology Industry Organization (BIO), the 13th Annual CEO & Investor Conference will take place February 14th and 15th at the Waldorf-Astoria Hotel in New York.

A live audio link to the webcast presentation is available at:, or on the company’s website at   It is recommended that listeners log on 15 minutes in advance of the
presentation to register and download any necessary software.

An audio replay will be accessible approximately one hour following the
presentation on the Oncolytics website.

About the BIO CEO and Investor Conference
Now in its thirteenth year, the BIO CEO & Investor Conference 2011 is
the largest independent investor conference focused on publicly-traded
biotechnology companies. Each year the BIO CEO & Investor Conference
provides a neutral forum where institutional investors, industry
analysts, and senior biotechnology executives have the opportunity to
shape the future investment landscape of the biotechnology industry.
The conference features issue-oriented plenary sessions, educational
sessions focused on hot therapeutic areas and key business issues,
company presentations, one-on-one meetings, and networking
opportunities. For more information, visit

About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the
development of oncolytic viruses as potential cancer therapeutics. 
Oncolytics’ clinical program includes a variety of human trials
including a Phase III trial in head and neck cancers using REOLYSIN®, its proprietary formulation of the human reovirus. For further
information about Oncolytics, please visit:

The presentation and webcast times are subject to change. This release
and the presentation related thereto contain forward-looking statements
which involve known and unknown risks, delays, uncertainties and other
factors not under the Company’s control and which may cause actual
results, performance or achievements of the Company to be materially
different from the results, performance or expectations implied by
these forward-looking statements
. Such risks and uncertainties include, among others, the efficacy of
REOLYSIN as a cancer treatment, the success and timely completion of
clinical studies and trials, uncertainties related to the research and
development of pharmaceuticals and uncertainties related to the
regulatory process. Investors should consult the Company’s quarterly
and annual filings with the Canadian and U.S. securities commissions
for additional information on risks and uncertainties relating to the
forward-looking statements. Investors are cautioned against placing
undue reliance on forward-looking statements. The Company does not
undertake to update these forward-looking statements, except as
required by applicable laws.

SOURCE Oncolytics Biotech Inc.